RET rearrangement was first identified in PTC, hence designated as RET/PTC, in which the RET tyrosine kinase domain is fused to the N-terminus of a partner gene, resulting in ligand-independent constitutive kinase activation (34), which can activate both MAPK and PI3K pathways, causing oncogenesis and tumor progression (35). This evidence concerns the gene RET and neoplasm.